Nuvation Bio announced on Thursday, September 17, 2026 that the FDA approved a supplemental New Drug Application updating the IBTROZI (taletrectinib) label for locally advanced or metastatic ROS1-positive non-small cell lung cancer. The label now reports a median duration of response of 49.7 months in TKI-naive patients in the Phase 2 TRUST-I study, based on a median follow-up of 51 months and an August 2025 data cutoff that added 14 months of data from TRUST-I and TRUST-II. Nuvation said the approval came four months ahead of the PDUFA date and brought no changes to the label's safety sections. IBTROZI, which Nuvation describes as a CNS-active next-generation ROS1 inhibitor, was first approved on June 11, 2025; Innovent Biologics markets it in China as DOVBLERON.
Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist peptide, with Kailera's US Phase 3 planned H1 2027); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.
Chinese biotech GLP-1 pipeline activity added depth across the week. Minwei Bio's MWN105 registered two clinical trials on August 19-20, 2026: Phase Ib (CTR20253330) targeting semaglutide-intolerant populations (patients unable to reach target Wegovy or Ozempic doses due to GI side effects, roughly 5-10% of real-world users), and Phase II (CTR20253336) covering non-diabetic overweight and obese patients (BMI ≥30 or BMI 27-30 with weight-related comorbidities). Innovent Biologics IBI3032 received FDA IND clearance August 5, 2026 for a US Phase 1 study, and on August 22 a Chinese CTR registration (CTR20253396) was activated for synchronized dual-region development. The Chinese biotech GLP-1 pipeline continues to expand across multiple programs including Hengrui-Kailera's ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), Innovent's mazdutide (GLP-1/glucagon dual agonist in late-stage Chinese and US trials), and multiple novel candidates targeting differentiated patient populations. The semaglutide-intolerant population is a real gap in the current commercial landscape: patients who cannot tolerate GI side effects at 1.7 mg or 2.4 mg semaglutide often plateau at sub-therapeutic doses. A drug specifically designed for that population would address an under-served segment. The dual-region synchronized development pattern (China IND filings + US CTR / FDA IND filings in parallel) reflects Chinese biotechs' increasing sophistication at multi-market clinical strategy.